Literature DB >> 19040984

Outcomes in reoperative thyroid cancer.

Francis P Ruggiero1, Fred G Fedok.   

Abstract

The recommended initial treatment for locoregional recurrence of thyroid cancer is surgery. Of most value to the surgeon considering reoperation for thyroid cancer is the impact that such procedures have on patient survival; the data in this regard are limited. Also of great interest to the surgeon is morbidity associated with reoperation. Because these patients have already had a total or near total thyroidectomy, reoperation requires a surgical revisiting of an already operated bed; intuitively, one might predict a higher rate of complications owing to scar tissue. This article reviews the evidence regarding rates of various complications.

Entities:  

Mesh:

Year:  2008        PMID: 19040984     DOI: 10.1016/j.otc.2008.06.003

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  3 in total

1.  Recurrent differentiated thyroid cancer: to cut or burn.

Authors:  Roberto Cirocchi; Stefano Trastulli; Alessandro Sanguinetti; Lorenzo Cattorini; Piero Covarelli; Domenico Giannotti; Giorgio Di Rocco; Fabio Rondelli; Francesco Barberini; Carlo Boselli; Alberto Santoro; Nino Gullà; Adriano Redler; Nicola Avenia
Journal:  World J Surg Oncol       Date:  2011-08-12       Impact factor: 2.754

2.  A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancer.

Authors:  Andrew M Thompson; Robin M Turner; Andrew Hayen; Ahmad Aniss; Salvatore Jalaty; Diana L Learoyd; Stan Sidhu; Leigh Delbridge; Michael W Yeh; Roderick Clifton-Bligh; Mark Sywak
Journal:  Thyroid       Date:  2014-01-24       Impact factor: 6.568

3.  Bronchoscopic interventions combined with percutaneous modalities for the treatment of thyroid cancers with airway invasion.

Authors:  Hongwu Wang; Meimei Tao; Nan Zhang; Lingfei Luo; Dongmei Li; Hang Zou; Yunzhi Zhou; Sujuan Liang
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-19       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.